Volume seems to be drying up on RX.V

RX.V / BIOYF presentation

https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnxiaW9zeWVudHxneDoxYjA3MzgzYzdjNDM5NWM5

BioSyent Releases Q4 and Full Year 2015 Results

https://finance.yahoo.com/news/biosyent-releases-q4-full-2015-130000280.html

that .18 eps was for trailing 12 months.

BIOYF going nuts today. Nice earnings release. $0.18 annualized at $0.72 (not looking at trending so not sure that is realistic) for an $8.00 stock looks pretty good!

This is more than a 10 bagger from where I started buying a couple of years ago. I remember buying ten thousand and fifteen thousand shares at a time at .26. Wish I still had the 280K shares I had a year ago. Oh well.

Thanks so much Zenlunatic!

Do you see now? eom

BioSyent Pharma Signs Exclusive Licence and Distribution Agreement for a New Women's Health Product Already Approved by Health Canada-2014 Launch Planned

TORONTO, ONTARIO--(Marketwired - Oct. 1, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian Licence and Distribution Agreement with its third European partner for a women's health product that has prior approval from Health Canada.

The product has been widely approved in Europe and is successfully marketed in countries such as Germany, France, Italy, Spain, Sweden, Poland, Austria, and Belgium. "Pre-launch preparations have commenced and we are planning for a first half 2014 launch of this new product," said René Goehrum, BioSyent CEO. "It will be a good complement to both our promotion activities for FeraMAX® 150 and our Hospital Products Division."

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contact:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

This isn't the venue to discuss stocks other than BioSyent. There is another Canadian stock I own and it is INX.V. However, if you want to discuss this or other Canadian stocks further, let's discuss them on the SwingTrade board:

http://investorshub.advfn.com/SwingTrade-Member-Forum-SWING-1781/

Canadian insider is usually a few days behind. TMx money also shows some funds buying as insider buying. Seems like good news on way as stock is doing very well. Are there any other good canadian microcaps that you are following. RX and nci are my two favorites.

That looks wrong as there is no recent insider buying. There is recent insider selling but this is from the individual that is running the old insecticide business.

http://www.canadianinsider.com/node/7?menu_tickersearch=rx

Interesting!

http://www.tmxmoney.com/TMX/HttpController?GetPage=InsiderTradeMarker&Market=V&Language=en

Good day, people,

Does anyone have any insight as to where we expect to go?

Looks good so far.

Cheers!

I sold just enough today that I'm riding free shares.

Yay me! :)

Yes!

Nice close at 2.00

BioSyent is in with another great quarter. They continue to grow like clockwork. Diluted EPS was $0.029/share. Their pipeline indicates continued long term growth.

BioSyent Releases Q2 and Six Month Results: Six Month Sales Increase 57% and Profit Before Tax Up 68%

TORONTO, ONTARIO--(Marketwired - Aug. 22, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its second quarter (Q2) and first half (H1) 2013 financial results for the three and six months ending June 30, 2013.

- Q2 2013 Sales of $1,786,685 increased by 47% versus Q2 2012
- First six months (H1) 2013 Sales of $3,328,528 increased by 57% versus H1 2012
- Q2 2013 Pharmaceutical Sales of $1,683,793 were up by 60% versus Q2 2012, and 29% versus Q1 2013
- H1 Pharmaceutical Sales of $2,991,303 increased by 65% versus H1 2012
- Fifteen consecutive quarters of continued pharmaceutical sales growth
- Q2 2013 Income Before Tax of $542,964 increased by 61% versus Q2 2012
- Q2 2013 Tax Expense was $124,639 versus nil in Q2 2012
- Q2 Net Income After Tax of $418,325 increased by 24% versus Q2 2012
- H1 2013 Income Before Tax of $1,024,927 increased by 68% versus H1 2012
- H1 2013 Tax was $262,192 versus nil in H1 2012 (H1 2013 Tax equivalent to $0.02/share)
- H1 2013 Net Income After Tax of $762,735 increased by 25% compared to H1 2012
- H1 2013 basic earnings per share of $0.06 versus $0.05 in H1 2012
- H1 2013 Cash Generation of $313,595 represents a 396% increase over the prior year period
- FeraMAX® Powder, an innovative new product, was launched in June 2013
- Selected as a TSX Venture 50 Top Performer for two consecutive years - 2012 and 2013
- Named as one of Canada's fastest growing companies in the Profit 500 rankings for 2013
- 2 New Products submitted to Health Canada for marketing approval

Total sales for Q2 2013 of $1,786,685, were 47% higher compared to $1,216,115 in the corresponding prior year period. Total sales for H1 2013 of $3,328,528, were 57% higher than H1 2012.

Income Before Tax for Q2 2013 was $542,964, which is 61% higher than $337,437 in Q2 2012. Income Before Tax for H1 2013 was 1,024,927, an increase of 68% over the corresponding prior year period.

H1 2013 has a tax provision of $262,192 whereas there was no tax provision in H1 2012 due to available carry forward losses from previous years. In spite of this difference in tax expense, Net Income After Tax increased by 25% from $610,620 in H1 2012 to $762,735 in H1 2013.

Working capital, which is the difference between current assets and current liabilities, has increased by 33% from $2,509,278 as at December 31, 2012 to $3,336,433 as at June 30, 2013. Cash accounted for 79% of working capital as at June 30, 2013. Total Cash on June 30 2013 was $2,629,650. Total Shareholder's Equity increased by 29% from $2,839,409 at December 31, 2012 to $3,663,185 at June 30, 2013. This is mainly due to an increase in retained earnings for H1 2013.

The Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on August 22, 2013.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

BioSyent will also release a CEO presentation on the Second Quarter Financial Results at the following link: www.biosyent.com/q2/.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

BioSyent Inc. 	  
 Interim Consolidated Statement of Comprehensive Income 	  
 (Unaudited - Abbreviated) 	  
   	  	  	  	  	  	  	  	  	  	  	  	  
 In Canadian Dollars 	Q2 
 2013 	  	Q2 
 2012 	  	% 
 Change 	  	H1 
 2013 	  	H1 
 2012 	  	% 
 Change 	  
 Revenues 	1,786,685 	  	1,216,115 	  	47 	% 	3,328,528 	  	2,120,603 	  	57 	% 
 Cost Of Goods Sold 	387,337 	  	250,065 	  	55 	% 	695,806 	  	438,661 	  	59 	% 
 Gross Profit 	1,399,348 	  	966,050 	  	45 	% 	2,632,722 	  	1,681,942 	  	57 	% 
 Total Operating Expense 	856,384 	  	628,613 	  	36 	% 	1,607,795 	  	1,071,322 	  	50 	% 
 Profit Before Tax 	542,964 	  	337,437 	  	61 	% 	1,024,927 	  	610,620 	  	68 	% 
 Tax (including Deferred Tax) 	124,639 	  	- 	  	NA 	  	262,192 	  	- 	  	NA 	  
 Profit After Tax 	418,325 	  	337,437 	  	24 	% 	762,735 	  	610,620 	  	25 	% 
 Profit After Tax % to Sales 	23 	% 	28 	% 	  	  	23 	% 	29 	% 	  	  
   
 BIOSYENT INC. 
 INTERIM UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 
 (Unaudited - Abbreviated) 
   
 AS AT 	June 30, 
 2013 	December 31, 
 2012 	% 
 Change 	  
 ASSETS 	  	  	  	  
   	  	  	  	  
 Receivables 	1,074,972 	589,697 	82 	% 
 Inventory 	796,908 	345,630 	131 	% 
 Prepaid expenses & deposits 	162,463 	71,257 	128 	% 
 Cash & Cash Equivalents 	2,629,650 	2,316,055 	14 	% 
 Current Assets 	4,663,993 	3,322,639 	40 	% 
   	  	  	  	  
 Equipment 	122,379 	97,932 	25 	% 
 Deferred Tax 	204,373 	232,199 	-12 	% 
 TOTAL ASSETS 	4,990,745 	3,652,770 	37 	% 
   	  	  	  	  
 LIABILITIES AND SHAREHOLDERS' EQUITY 	  	  	  	  
   	  	  	  	  
 Current Liabilities 	1,327,560 	813,361 	63 	% 
 Total Equity 	3,663,185 	2,839,409 	29 	% 
 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 	4,990,745 	3,652,770 	37 	%

The statutory tax rate for them in Canada has been 28.25% Although I think it dropped to 26.5% based upon their annual report. They do have some income in the US too but the vast majority of their income is Canadian. As of the end of 2012 they had a deferred tax asset of $232,199.

In Q1'2013 they accrued taxes at the rate of 28.5%. I would expect the same going forward although I think it could vary a bit.

Hey Mike, do you have any idea what coporate tax rates are in Canada so we know what to expect as far as taxes? It's been a while since I looked at biosyents financial statements. But don't they have a tax asset now? Can that be used to offset any more future ttaxes?

Thanks in advance.

It is looking good!

RX.V $1.39 Getting close, just need another big day of volume and my guess is we breakout.

http://screencast.com/t/htc1A6QUPh

BioSyent Pharma Launches New FeraMAX(R) Powder-Water Soluble Polysaccharide-Iron Complex Iron Supplement

TORONTO, ONTARIO--(Marketwired - June 6, 2013) - BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of its unique new oral iron supplement - FeraMAX® Powder.

FeraMAX® Powder is the first innovation in the pediatric oral iron market in Canada in almost 50 years. The Canadian market launch will be the global introduction of this new product and provides BioSyent Pharma with a unique offering for international marketing partners.

FeraMAX® Powder joins FeraMAX® 150 in providing healthcare professionals and their patients with a safe, effective, and well tolerated oral iron supplement. It is indicated for the prevention of iron deficiency and iron deficiency anaemia in newborns, infants, children and adults.

FeraMAX® Powder is the only oral iron product available in a dissolvable powder and comes in pleasant tasting grape/raspberry flavoured gluten and alcohol-free crystals which can be conveniently dosed by diluting in water or mixing with soft foods. This innovative new product is based upon the same doctor recommended, proprietary, non-ionic polysaccharide-iron complex technology found in FeraMAX® 150.

Other oral iron products intended for infants and children either have an unpleasant heavy metallic taste which deter patient compliance or they come in formulations containing alcohol which healthcare professionals and caregivers prefer to avoid. In addition to its clear advantages in the pediatric market, FeraMAX® Powder is also well suited for adult patients that have difficulty swallowing pills.

FeraMAX® Powder was exhibited at the recent Primary Care Today medical conference attended by over 3,000 healthcare professionals. Listings have been secured at major wholesalers and shipments of FeraMAX® Powder, to over 30 wholesale distribution centres supplying pharmacies across Canada, will commence over the next week.

"The launch of FeraMAX® Powder further strenghtens BioSyent Pharma's leadership position in providing innovative iron supplement solutions for healthcare professionals and their patients" said René Goehrum, President and CEO of BioSyent. "We now have a full range of solutions and dosing options available for all iron deficient and iron deficient anaemia patients".

For more information regarding FeraMAX® Powder and FeraMAX® 150, visit www.feramax.com

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Contact:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 Year Revenue Growth Rate of 355%

TORONTO, ONTARIO--(Marketwired - June 4, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that PROFIT Magazine has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2013 rankings. Published in the Summer issue of PROFIT Magazine and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2007-2012) growth rate of 355%, BioSyent ranked #183 on the PROFIT 500 list.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

About PROFIT Magazine and PROFITguide.com

PROFIT: Your Guide to Business Success is Canada's preeminent publication dedicated to the management issues and opportunities facing small and mid-sized businesses. For 31 years, Canadian entrepreneurs and senior managers across a vast array of economic sectors have remained loyal to PROFIT because it's a timely and reliable source of actionable information that helps them achieve business success and get the recognition they deserve for generating positive economic and social change. Visit PROFIT online at PROFITguide.com.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Contact:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com

BioSyent Pharma Submits Two New Drugs to Health Canada for Marketing Approval

TORONTO, ONTARIO--(Marketwired - May 23, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that its subsidiary, BioSyent Pharma Inc., has submitted two new drug products to Health Canada seeking marketing approval.

These two urgent care drugs are supplied in a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies and will complement BioSyent's Hospital Division.

"These two products are consistent with our strategy of sourcing unique and innovative pharmaceutical products for the Canadian market," said René Goehrum, President and CEO of BioSyent. "There are additional products under development by our European partner and we look forward to exploring additional product candidates utilizing the same patented technology. Due diligence on the next product has already commenced."

The products will be launched after Health Canada grants marketing approval.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Contact:
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

I like it!

That is another excellent report for BIOYF / RX.V!

BioSyent Releases First Quarter Results-Sales Increase 70%, Profit Before Tax Up 76%

TORONTO, ONTARIO--(Marketwired - May 22, 2013) - BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") released today a summary of its First Quarter (Q1) 2013 financial results.

- Q1 2013 Sales of $1,541,843 increased by 70% versus Q1 2012
- Q1 2013 Pharmaceutical Sales were up by 72% versus Q1 2012
- Net Income Before Tax increased by 76% in Q1 2013 versus Q1 2012
- Q1 2013 Tax was $137,553 compared to $0 in Q1 2012
- Q1 2013 Net Income After Tax of $344,410 increased by 26% compared to Q1 2012
- Q1 2013 basic earnings per share of $0.03 versus $0.02 in Q1 2012
- Selected as a TSX Venture 50 Top Performer for two consecutive years - 2012 and 2013

Total sales for Q1 2013 of $1,541,843, were 70% higher compared to $904,488 in the corresponding prior year period.

Net Income Before Tax for the first quarter of 2013 was $481,963, which is 76% higher than $273,184 in the first quarter of 2012.

The first quarter of 2013 has a tax provision of $137,553 whereas there was no tax provision in Q1 2012 due to available carry forward losses from previous years. In spite of this, Net Income After Tax increased by 26% from $273,184 in Q1 2012 to $344,410 in Q1 2013. The Total Comprehensive Income of $348,354 for Q1 2013 was 28% higher than that of $272,852 in Q1 2012.

Working capital, which is the difference between current assets and current liabilities, has increased by 16% from $2,509,278 as at December 31, 2012 to $ 2,913,609 as at March 31, 2013.Total Shareholder's Equity increased by 14% from $2,839,409 at December 31, 2012 to $3,232,464 at March 31, 2013. This is mainly due to increase in retained earnings for Q1 2013.

The Financial Statements and Management's Discussion & Analysis will be posted on www.sedar.com on May 22, 2013.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

BioSyent Inc. Interim Consolidated Statement of Comprehensive Income 
 (Unaudited - Abbreviated) 
   	3 months ended March 31 
 In Canadian Dollars 	2013 	2012 	% Change 
 Revenues 	1,541,843 	904,488 	70% 
 Cost of Goods Sold 	308,469 	188,596 	64% 
 Gross Profit 	1,233,374 	715,892 	72% 
 Total Operating Expenses 	751,411 	442,708 	70% 
 Profit Before Tax 	481,963 	273,184 	76% 
 Tax (including Deferred Tax) 	137,553 	- 	  
 Profit After Tax 	344,410 	273,184 	26% 
 Profit After Tax % to Sales 	22.3% 	30.2% 	  
   
 BioSyent Inc. Interim Consolidated Statement of Financial Position 
 (Unaudited - Abbreviated) 
 AS AT 	March 2013 	December 2012 	% Change 
 ASSETS 	  	  	  
 Receivables 	1,109,951 	589,697 	88% 
 Inventory 	327,137 	345,630 	-5% 
 Prepaids 	86,651 	71,257 	22% 
 Cash and Cash Equivalents 	2,123,348 	2,316,055 	-8% 
 Current Assets 	3,647,087 	3,322,639 	10% 
 Equipment 	100,568 	97,932 	3% 
 Deferred Tax 	218,287 	232,199 	-6% 
 TOTAL ASSETS 	3,965,942 	3,652,770 	9% 
   	  	  	  
 LIABILITIES AND SHAREHOLDERS' EQUITY 	  	  	  
   	  	  	  
 Current Liabilities 	733,478 	813,361 	-10% 
 Total Equity 	3,232,464 	2,839,409 	14% 
 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 	3,965,942 	3,652,770 	9%

RX.V / BIOYF just continues to grow like clockwork.

B: BioSyent Releases Full Year 2012 Results-Sales Increase 79%, N
et Income Up 267%; 3 Year CAGR 70%; Q4 Sales Increase
B: BioSyent Releases Full Year 2012 Results-Sales Increase 79%, Net Income Up 26
7%; 3 Year CAGR 70%; Q4 Sales Increase 89% ( Marketwire )

TORONTO, ONTARIO, Mar 21, 2013 (MARKETWIRE via COMTEX) --
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a
summary of its Fiscal 2012 and Fourth Quarter (Q4) 2012 financial
results. Key highlights include:
-- Full year 2012 Sales of $5,024,154 increased 79% versus 2011
-- Revenue has grown at a compound annual growth rate of 70% over the last
three years
-- Net Income before Tax margin increased to 28% in 2012 from 15% in 2011
-- Full year 2012 Net Income after Tax of $1,541,317 increased 267%
compared to 2011
-- 2012 represented the 3rd consecutive year of profitability for the
Company
-- 2012 was the first year the Company paid income tax
-- EPS (Basic) was $0.12
-- The Company ended 2012 with $2,509,278 of working capital including
$2,316,055 of cash
-- The Company remains debt-free and has an unutilized operating line of
credit with Royal Bank of Canada
-- Selected as a TSX Venture 50 Top Performer for two consecutive years -
2012 and 2013

Total sales for Q4 2012 of $1,327,953, were 89% higher compared to
$703,337 in the corresponding prior year period. On a full year
basis, sales in 2012 of $5,024,154 were 79% higher than the previous
year sales of $2,808,666.

Net Income Before Tax for the fourth quarter of 2012 was $361,237
which is 454% higher than $65,220 in the fourth quarter of 2011. Net
Income Before Tax for full year 2012 was $1,399,122 or 233% higher
than $420,392 in corresponding prior year 2011. The Net Income before
Tax margin increased to 28% in 2012 from 15% in 2011. The Company has
chosen to use Net Income Before Tax as a key measure of performance
as it is independent of tax fluctuations that might occur due to the
utilization of carried forward loses from previous years or changes
in tax rates.

The Company has provided for an income tax liability of $90,004 for
the fourth quarter of 2012, for the first time. The Company has also
recognized a deferred tax credit for the first time - $232,199,
arising mainly from accumulated losses carried forward from previous
years while correspondingly recognizing a deferred tax asset of like
value on its consolidated statements of financial position. The full
year 2012 Net Income after Tax (NIAT) of $1,541,317 increased 267%
compared to $420,392 in 2011. Without the one-time recognition of the
deferred tax credit, Net Income after Tax for full year 2012 would
have been $1,309,118. The Total Comprehensive Income of $1,539,317
for 2012 was 268% higher than that of $417,950 in 2011. Earnings per
share (EPS) for full year 2012 were $0.12 Basic and $0.11 Diluted
compared to $0.03 Basic and $0.03 Diluted in 2011.

Working capital, which is the difference between current assets and
current liabilities, has increased by 122% from $1,128,065 as at
December 31, 2011 to $ 2,509,278 as at December 31, 2012. Cash and
cash equivalents on December 31, 2012 of $2,316,055 were 92% of
working capital compared to 94% as at December 31, 2011. Cash
Generation, or the increase in Cash and Cash Equivalents, of
$1,258,009 in 2012, represents a 114% increase over $586,951 in the
prior year period.

The Financial Statements and Management's Discussion & Analysis will
be posted on www.sedar.com on March 21, 2012. The launch of
FeraMAX(R) Powder has been delayed due to scale-up of production.

For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX",
BioSyent is a profitable growth oriented specialty pharmaceutical
company which searches the globe to in-license or acquire innovative
pharmaceutical products that have been successfully developed, are
safe and effective, and have a proven track record of improving the
lives of patients and supporting the healthcare professionals that
treat them.

Once a product of interest has been found, BioSyent then acquires the
exclusive rights to the product and manages it through the Canadian
governmental regulatory approval process. Once approved, BioSyent
markets the product throughout Canada.

At the date of this press release the Company had 13,271,195 shares
issued and outstanding.

Trading on a stock like this depends upon your timeframe IMO. I believe the long term trend is up but there are swings in the interim. In general I tend to trade around a core position. In this strategy I sell some when I think the stock is getting ahead of itself and buy some when the price drops too much. Often times that is easier said than done. The best strategy may vary for each person depending upon their ability to watch the market, tax considerations, etc.

Mike, thanks for bringing Biosyent to the Swing Trader board! I have a couple questions if you don't mind answering-
What is your trading strategy with a stock like this?
Buy and hold through ups and downs for a much higher future price? (the future does look very bright)
Trade around a core position?
Swing trade your whole position?
Do you have a technical price target?
This seems to be repeating last fall, quick climb to the 1.40 level with lots of volume and then resistance. Weighing my options and watching for a similar re-tracement. TIA.

BioSyent Named to the 2013 TSX Venture Top 50(R) Ranking-2nd Consecutive Year Chosen as a Top TSX Performer

TORONTO, ONTARIO--(Marketwire - Feb. 14, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has been named as one of the TSX Venture Top 50 companies.

The 2013 TSX Venture 50 is an annual ranking of strong performing emerging companies listed on the TSX Venture Exchange. The TSX Venture 50 includes the top 10 companies in five major industry sectors that have been identified as leaders in Canada's public venture market. BioSyent is ranked seventh in the list of ten leading Technology and Life Sciences companies for the year. Companies are selected based on four equally weighted criteria - return on investment, trading activity, market capitalization growth, and analyst coverage. The results were obtained from data to December 31, 2012.

"With more than 2,200 companies listed on the TSX Venture Exchange, it is an honour to have BioSyent named for two consecutive years as one of the TSX Venture Top 50 companies," said René Goehrum, President and CEO of BioSyent Inc. "Our business has progressed considerably since we were named to the 2012 TSX Venture 50. Being named to the 2013 TSX Venture 50 is further investor validation of our business model and results."

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications, which occupy a niche in the market, are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com

BioSyent Presents at MicroCapClub Invitational

TORONTO, ONTARIO--(Marketwire - Feb. 12, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has been selected to present at the first ever MicroCapClub Invitational.

The presentation can be accessed at the following link: http://microcapclub.com/2013/02/microcapclub-invitational-biosyent-rx-v/.

"At MicroCapClub we have over 170 experienced microcap investors discussing over 90 microcap companies in our members forum, and we thought as a group it would be great to showcase a few companies we believe are highly unique," said Ian Cassel, founder of MicroCapClub. "We have been following BioSyent for about a year and have been impressed with the company's profitable growth trajectory. BioSyent's strategy to in-license certain niche pharmaceutical products and distribute them in Canada has proven to be very successful. We look forward to following the company's progress in 2013 and beyond as they market and distribute additional products."

"At BioSyent we are excited about our business," said René Goehrum, President and CEO of BioSyent Inc. "We are pleased with our results over the last 2 1/2 years, the foundation that we have built, and our prospects for continued growth. We look forward to sharing our continuing progress with investors as 2013 unfolds."

About MicroCapClub: The MicroCapClub (mc2) is an exclusive microcap forum focused on microcap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded microcap investors. Our goal at MicroCapClub is quality membership and quality stock ideas. If you are an experienced microcap investor, feel free to Apply Today. Go to www.microcapclub.com for additional information.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com

RX.V / BIOYF did a presentation that I recommend viewing:

http://microcapclub.com/2013/02/microcapclub-invitational-biosyent-rx-v/

More insider buys for BIOYF/RX.V were posted.

Dec 21/12 Dec 21/12 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 2,000 $0.870
Dec 21/12 Dec 20/12 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 1,000 $0.870

http://www.canadianinsider.com/node/7?menu_tickersearch=rx

RX.V volume was 173,933. That is roughly 5x the average daily volume. RX.V closed at C$1.01 which was up $0.13 for the day.

That was a very nice quarter for BIOYF / RX.V. They are now up to 12 sequential quarters of increasing pharmaceutical sales!

BioSyent Releases Third Quarter Results; Record Quarterly Sales and Profit: Sales Up 60%, Profit Up 79%

TORONTO, ONTARIO--(Marketwire - Nov 15, 2012) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its Third Quarter (Q3) 2012 financial results.

- Q3 2012 Sales of $1,575,598 sets an all time quarterly record and grew by 60% over Q3 2011
- Q3 2012 Pharmaceutical Sales of $1,180,718 grew by 95% vs. $604,523 in Q3 2011
- Sales for the nine months ended September 30, 2012 of $3,696,201 grew by 76% over the prior year period
- Total Comprehensive Income for Q3, 2012 of $423,015 hit an all time quarterly record and was higher than that of 2011 by 79%
- Total Comprehensive Income for the nine months ended September 30, 2012 of $1,034,828 grew by 196% over the corresponding prior year period
- Cash generation of $878,751 for the nine months ended September 30, 2012 increased by 147% over the corresponding period in 2011
- Q3 2012 basic earnings per share (EPS) were $0.03
- Cumulative Basic EPS over the last 4 consecutive quarters is $0.09

Total Sales for Q3 2012 hit a new quarter record and were $1,575,598 or 60% higher compared to $983,857 in the corresponding prior year period and 30% higher than the immediately preceding quarter (Q2 2012) which had sales of $1,216,115. For the nine months ended September 30, 2012, the Total Sales of $3,696,201 were 76% higher than the corresponding prior year period.

Pharmaceutical Sales were $1,180,718 in Q3 2012, or 95% higher than the corresponding prior year period sales which were $604,523. For the nine months ended September 30, 2012, Pharmaceutical Sales of $2,996,115 were 115% higher than $1,392,334 in the corresponding prior year period.

The Company earned Total Comprehensive Income of $423,015 in Q3 2012, which was 79% higher than the Total Comprehensive Income of $235,999 in Q3 2011. For the nine months ended September 30, 2012, the Total Comprehensive Income of $1,034,828 was 196% higher than $349,452 in the corresponding prior year period.

Working capital has increased by 94% from $1,128,065 as at December 31, 2011 to $2,184,891 as at September 30, 2012. Cash and cash equivalents on September 30, 2012 were 89% of working capital compared to 94% as at December 31, 2011. Total Cash generation for the nine months ended September 30, 2012 of $878,751 increased by 147% over the corresponding prior year period.

The Company''s subsidiary BioSyent Pharma Inc. is completing preparations for a Q1 2013 launch of FeraMAX® Powder which was approved by Health Canada earlier this year.

The Financial Statements and Management''s Discussion & Analysis will be posted on www.sedar.com on November 15, 2012.

As at the date of this press release the Company had 12,921,195 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company''s legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com

I forgot to post this here, but this is an article I wrote on BioSyent.

http://microcapclub.com/2012/10/my-secret-recipe-shopping-and-a-taste-test/

I'm surprised there isn't more chatter on BioSyent too.

I have heard that the price run up was due to a high rating of BioSyent by VectorVest.

Things have really quieted down - with both the action of the stock and volume, and 'chatter' about the company. I am a little surprised more haven't gotton on board. I know there are companys with lower PE's out there, but here you can have confidence in what will be going on one year or three years from now.

Any idea on who ran the price up last month? I wrote a little blurb on the company and posted it on Ian's website. Never heard back, guess he took it down.

There is a web site for Cathejell Jelly 2%:

http://www.cathejell.ca

By my count, 1,709,300 shares have traded under the symbol RX.V since earnings came out. We can add in some more shares that traded only in the US but I don't know how to get a precise count as you can't just add the shares that traded under BIOYF. My guess is that the correct count is somewhere around 1.8M shares. That is around 21% of the float! That is great to see as often a new set of investors are required to take the stock to the next level.

There were more insider buys on RX.V / BIOYF reported yesterday. A total of 23,676 shares were purchase. The transactions included 16,478 shares purchased at C$1.19 and 7,198 shares purchased at C$1.25. Note that these prices are considerably higher than the last trade of C$1.07.

http://www.canadianinsider.com/node/7?menu_tickersearch=rx

There were more insider purchases of RX.V / BIOYF!
http://www.canadianinsider.com/node/7?menu_tickersearch=RX+|+BioSyent

BIOYF / RX.V has had two days of huge volume. Today the volume for RX.V was 106,910 shares. Yesterday, it was 139,800 shares. Average volume is only 15,814 shares.

Nice report!

Looks like .03 Mike, just like you thought.

http://finance.yahoo.com/news/biosyent-releases-second-quarter-results-212100431.html

Yes

It sounds like these products have unique charachteristics and some strong selling points.